Felicia Davatolhagh is a postdoctoral researcher at the University of California, Los Angeles in Anne Churchland’s lab, where she studies how cortical circuits are altered during decision-making in a genetic mouse model of autism. She also serves as a member of the neurobiology department’s Justice, Diversity and Inclusion (JEDI) group.
Felicia Davatolhagh
Postdoctoral researcher
University of California, Los Angeles
From this contributor
Women are systematically under-cited in neuroscience. New tools can change that.
An omitted citation in a high-profile paper led us to examine our own practices and to help others adopt tools that promote citation diversity.
Women are systematically under-cited in neuroscience. New tools can change that.
By
Anne Churchland, Felicia Davatolhagh
22 July 2024 | 5 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read